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Abstract
Deficits in sensorimotor gating measured by prepulse inhibition (PPI) of the startle have been known as characteristics of
patients with schizophrenia and related neuropsychiatric disorders. PPI disruption is thought to rely on the activity of the
mesocorticolimbic dopaminergic system and is inhibited by most antipsychotic drugs. These drugs however act also at the
nigrostriatal dopaminergic pathway and exert adverse locomotor responses. Finding a way to inhibit the mesocorticolimbic-
without affecting the nigrostriatal-dopaminergic pathway may thus be beneficial to antipsychotic therapies. The melanin-
concentrating hormone (MCH) system has been shown to modulate dopamine-related responses. Its receptor (MCH1R) is
expressed at high levels in the mesocorticolimbic and not in the nigrostriatal dopaminergic pathways. Interestingly a
genomic linkage study revealed significant associations between schizophrenia and markers located in the MCH1R gene
locus. We hypothesize that the MCH system can selectively modulate the behavior associated with the mesocorticolimbic
dopamine pathway. Using mice, we found that central administration of MCH potentiates apomorphine-induced PPI
deficits. Using congenic rat lines that differ in their responses to PPI, we found that the rats that are susceptible to
apomorphine (APO-SUS rats) and exhibit PPI deficits display higher MCH mRNA expression in the lateral hypothalamic
region and that blocking the MCH system reverses their PPI deficits. On the other hand, in mice and rats, activation or
inactivation of the MCH system does not affect stereotyped behaviors, dopamine-related responses that depend on the
activity of the nigrostriatal pathway. Furthermore MCH does not affect dizocilpine-induced PPI deficit, a glutamate related
response. Thus, our data present the MCH system as a regulator of sensorimotor gating, and provide a new rationale to
understand the etiologies of schizophrenia and related psychiatric disorders.
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Introduction
Prepulse inhibition (PPI) is the phenomenon where a startle
response produced by an intense stimulus (pulse) is suppressed
when a weak prestimulus (prepulse) immediately precedes it. PPI is
observed in many species from laboratory animals to human [1–3]
and has been used as a behavioral paradigm to measure
sensorimotor gating. Significant PPI deficits have been observed
in patients with schizophrenia and other psychopathological
disorders associated with dopamine (DA) dysregulation [1,3–5].
These deficits in PPI are thought to underlie problems with
inhibitory mechanisms in sensorimotor gating, for example
sensory overload [4,6,7].
The mesocorticolimbic dopaminergic system has been shown to
be involved in modulating PPI [3]. For instance, DA infusion into
the nucleus accumbens disrupts PPI [8,9]. PPI deficits induced by
psychotomimetic administration can be reversed by antipsychotic
drugs [2]. Both typical and atypical antipsychotics reverse
apomorphine-induced PPI deficits in rats and their ability to
reverse these deficits has been shown to correlate with clinical
efficacy and their affinity for D2R [10,11]. PPI in rodents is thus a
useful animal model to predict antipsychotics’ efficacy. Other
neurotransmitter systems acting independently of the DA system
are involved in PPI as well. Most notably, psychotomimetics acting
through the glutamate system such as phencyclidine (PCP) and
dizocilpine (MK-801) can induce PPI deficits in rodents [2,12,13].
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tially sensitive to dopaminergic drugs. For instance, rats that have
been pharmacogenetically selected for a high susceptibility to
apomorphine (so-called APO-SUS rats) show less PPI compared to
rats selected for a low susceptibility to apomorphine (so-called
APO-UNSUS rats) [14]. This is in line with the finding that APO-
SUS rats have a hyperactive mesolimbic dopaminergic system
when compared to the APO-UNSUS rats [15,16]. The APO-SUS
rats have been described as an animal model displaying certain
aspects of schizophrenia (for review [17]).
Stereotypies represent another symptom observed in people
with neuropsychiatric disorders [18,19]. Stereotypies are repetitive
and purposeless behaviors such as head banging and body rocking.
They are also found in chronic cocaine or amphetamine users
[20–22] and in Parkinson’s patients treated with a high dose of DA
agonists [23,24] which points to the importance of DA in the
etiology of stereotypies. Systemic injections of DA agonists for
example amphetamine or apomorphine in laboratory animals
induce stereotyped behaviors such as constant sniffing, licking and
gnawing [25]. Indeed, efficacy of antipsychotics has often been
assessed by measuring their efficacy at reducing stereotypies. Yet
because the neuronal target important for stereotypic behavior is
the caudate putamen [26,27], these drugs often induce adverse
motor control responses. Finding a neuronal system that
modulates the mesolimbic dopaminergic system without interfer-
ing with the nigrostriatal system should provide an advantageous
basis for antipsychosis intervention. The melanin-concentrating
hormone (MCH) system represents a possible candidate.
MCH is a 19 amino acid cyclic peptide which is predominantly
expressed in the hypothalamus [28,29]. In rodents, MCH interacts
with one G protein-coupled receptor, MCH1R [30–34]. That
there may be a link between schizophrenia and the activity of the
MCH system has been suggested by a genomic linkage study
which revealed significant associations between schizophrenia and
a number of SNPs and haplotypes located in the MCH receptor
gene locus [35]. MCH1R is expressed in a number of brain
regions, but most notably at high levels in the mesocorticolimbic
dopamine pathway and at very low levels in the caudate putamen
[36]. The MCH system has been shown to be linked to the
activities of the dopamine system. In the nucleus accumbens shell
(NAcSh), MCH1R colocalizes with dopamine D1 and D2
receptors [37,38]. MCH potentiates D1R plus D2R agonist-
induced cellular firing [37] and decreases D1R agonist-induced
GluR1 phosphorylation [38,39]. MCH1RKO mice are hypersen-
sitive to amphetamine [40,41] and central MCH injections
increase cocaine-induced hyperactivity [37]. On the basis of these
in vitro and in vivo data, we hypothesize that the MCH system
may modulate the PPI of startle response without affecting
stereotypy. We therefore analyzed the effects of MCH on PPI in
mice injected with apomorphine or dizocilpine and in the APO-
SUS/ APO-UNSUS rat model and its effects on stereotypies.
Materials and Methods
Ethics Statements
All experimental procedures were reviewed and approved by
the institutional animal care and use committee of University of
California Irvine, USA and Radboud University Nijmegen, the
Netherlands (IACUC #2002-2343, DEC #2009-222).
Animals
Male C57BL/6 mice (NCI, Bethesda, MD), age 9–11 wks were
used. The generation of the APO-SUS and APO-UNSUS rat lines
with a high and low susceptibility for apomorphine, respectively,
has been described previously [42,43]. These rats were bred and
reared in the Central Animal Facility of the Radboud University
Nijmegen, the Netherlands. Male APO-SUS and APO-UNSUS
rats (age 9–12 wks) of the 30
th generation of the replicate line were
used for both behavioural tests and post-mortem processing of the
brain. Both mice and rats were group-housed and maintained on a
12-h light/dark cycle (lights on at 07:00) with food and water
available ad libitum. Rats were individually housed three days
before the PPI or stereotypy measurement to ensure that the
behavioral outcome of the animal was not affected by the behavior
of their cage mate(s) [14,43]. All experimental procedures were
performed in compliance with (inter)national and institutional
guidelines for the care and use of laboratory animals.
Drugs
Apomorphine or dizocilpine (Sigma-Aldrich, St. Louis, MO)
was dissolved in saline solution containing 0.1% ascorbic acid or in
saline solution respectively. Apomorphine or dizocilpine was
administered subcutaneously or intraperitoneally respectively.
Doses for the drugs were chosen based on previous reports (mice
[44] and rats [42]). MCH (Invitrogen, Carlsbad, CA) or MCH1R
antagonist, TPI 1361-17 [45] was dissolved in PBS containing
0.1% BSA (Fisher Scientific, Pittsburgh, PA) and was given i.c.v.
(mice [37], and rats [46]). Mice were slightly anesthetized with
isoflurane and MCH or TPI 1361-17 was transcranially injected
into the lateral ventricle by a freehand i.c.v. injection (for details:
[37]). Rats, which were also anesthetized with isoflurane, were
equipped with a unilateral guide cannula (for details: [46]).
Correct placement of injections was verified after the experiments
by histological examination and animals with misplaced i.c.v.
injections were excluded. Vehicle, MCH and/or TPI 1361-17 was
injected 5 min before apomorphine or dizocilpine injections. Rats
were tested for PPI, followed by exposure to the gnawing box one
week later. There was no repeat drug testing in the PPI
experiments of both mice and rats. In the first group of rats that
was used to test the effects of MCH on PPI, TPI 1361-17 was
given before exposure to the gnawing box. In the second group of
rats that was used to test the effects of TPI 1361-17 on PPI, MCH
was given before exposure to the gnawing box.
Acoustic Startle Procedure
Startle reactivity was measured according to previously
described procedures (for mice [44], for rats [43]) using San
Diego Instruments (San Diego, CA) startle chambers and SR-LAB
software. Each chamber had a clear nonrestrictive Plexiglas
cylinder resting on a platform inside of a ventilated and sound
attenuated box. A high frequency loudspeaker inside of each
chamber produced background noise of 65 dB for the mice studies
and 70 dB for the rat studies as well as the various acoustic stimuli
(see below). Vibrations of the Plexiglas cylinder caused by the body
startle response of the animal were converted into analog signals
by a piezoelectric accelerometer attached to the platform.
Calibration was performed every time used to ensure the accuracy
of the sound levels and startle measurements.
One week before drug testing, mice underwent a brief baseline
session to create treatment groups matched for baseline startle
reactivity and PPI response. During this baseline session, the
65 dB background noise was presented for 1 min and continued
throughout the remainder of the session. A total of 24 trials were
presented (18 of 120 dB pulse-alone trials and 6 of 77 dB
prepulse+120 dB pulse trials) in a pseudorandom order.
During testing sessions, mice or rats were placed in the startle
chambers and the background noise (see above) was presented for
a 5 min acclimatization period and continued throughout the test
The MCH System and Psychiatric Disorders
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no-stimulus trials. Prepulse trials consisted of a 20 msec prepulse,
80 msec delay, followed by a 40 msec (in mice) or 20 msec (in rats)
120 dB startle trial. Prepulse intensities were 3, 6 and 12 dB above
the 65 dB background noise in the mice studies and 3, 5 and
10 dB above the 70 dB background noise in the rat studies [43].
The no stimulus trials consisted of background noise only. This
represents a control trial for detecting differences in overall
activity. Startle trials, prepulse trials and no stimulus trials were
presented in a pseudorandom order and there was an average of
15 sec between the trials. Mice and rats were placed into the
startle chambers 5 min after drug injection.
The amount of PPI was calculated as a percentage score for
each acoustic prepulse intensity: % PPI=1002{[(startle response
for prepulse+pulse trials)/(startle response for pulse-alone tri-
als)]6100}. The magnitude of the response was calculated as the
average responses to all of the pulse-alone or prepulse trials.
In situ hybridization
In situ hybridization was performed similarly as previously
described [36,37] with slight modification. pMCH probe is a kind
gift from Dr. Jean-Louis Nahon (Institute de Pharmacologie
Moleculaire et Cellulaire, Valbonne, France) and previously
described [47]. The probe was digested with either SmaI or
HindIII, and then antisense and sense [
35S]-uridine 59-triphos-
phate (UTP)-labeled riboprobes were synthesized by T7 and T3
RNA polymerases, respectively (Amersham, Arlington Heights,
IL). Tissue sections were processed for in situ hybridization as
previously described with slight modifications. Briefly, 20 mm
sections were pretreated with proteinase K (0.1 mg/ml), acetylat-
ed, dehydrated through ethanol (50, 70, 95, and 100%), and air
dried. Pretreated sections were then incubated for 20 hours at
60uC, with hybridization buffer (50% formamide, 10% dextran
sulfate, 0.02% Ficoll, 0.02% polyvinylpyrolidone, 0.02% bovine
serum albumin, 500 mg/ml tRNA, 10 mM dithiothreitol, 0.3 M
NaCl, 10 mM Tris, pH 8.0, 1 mM EDTA, pH 8.0) containing
[
35S]-UTP labeled sense or antisense riboprobes (5610
6 cpm/
ml). After the sections were hybridized, they were treated with
RNase A (20 mg/ml) for 30 minutes at 37uC and then washed
four times in decreasing salinity (from 26to 0.16standard saline
citrate [SSC] buffer) and a 30-minute wash at 68uC. Next,
sections were dehydrated through ethanol (50, 70, 95, and
100%), air dried, and exposed to MR-1 Kodak film for 2 hrs.
Sections were processed further for cresyl violet staining.
Autoradiographic images were quantified using a computer-
based image analysis system (MCID, Image Research Inc., St
Catharines, ON, Canada). Brain areas on autoradiograms were
identified with reference to adjacent brain sections processed for
cresyl violet staining. MCH cells lateral to the fornix were
considered to be in the LH. Corresponding sections were
compared between APO-UNSUS and APO-SUS rats. Optical
densities in brain regions were measured (Figure S4) and the
corresponding values of radioactivity were determined by
interpolation from a standard curve, generated from C14
standards (American Radiolabeled Chemicals, St Louis, MO).
The values obtained represent the average of measurements
taken from 6 sections per animal (one final data point per animal)
in each brain site.
Stereotypy measurement in mice
Mice were individually placed in a new cage without bedding
and were allowed to habituate to this environment for 30 min.
These animals were then injected either with vehicle or MCH
(i.c.v.) 10 min prior to the apomorphine (s.c.) injection. At 5 min
after the apomorphine injection, stereotyped behaviors were
observed and recorded by an observer blind to the treatments
for 10 sec every minute for 30 min. Stereotypy rating scale was
slightly modified from a rating scale used by LaHoste and
Marshall [48]. 0=inactivity, 1=grooming, 2=locomotion,
3=sniffing directed upward, 4=sniffing with head down,
5=intense sniffing in a small circumscribed area, 6=intense
sniffing with bursts of lick, 7=constant licking or gnawing box,
8=self lick or biting. Rating scores for 30 min were collapsed and
shown as a total stereotypy counts.
Stereotypy measurement in rats
APO-SUS and APO-UNSUS rats were allowed to habituate to
the test room for 30 min and were then injected either with vehicle
or 10 nmole of MCH (i.c.v.) or 10 nmole of TPI 1361-17 (i.c.v.)
10 min prior to a systemic injection of 1.5 mg/kg of apomorphine
(s.c.). At 5 min after the apomorphine injection, stereotyped
behaviors were scored in a so-called gnawing box (for details see
[42]). This box was slightly modified from the box described by
Ljungberg and Ungerstedt [49] and contains 32 holes surrounded
by concentric ridges to promote stereotypic gnawing behavior. All
rats were placed in this box for 45 min and the total gnawing
count was automatically recorded.
Data analysis
Prism software (GraphPad, San Diego, CA) was used for
statistical analysis. Data was expressed as mean 6 SEM. Results
were analyzed by t-test or ANOVA followed by the appropriate
post hoc comparisons and p,0.05 was considered statistically
significant. In PPI analysis of mice (Figure 1, 2, 4), repeated-
measures two-way ANOVA with bonferroni post hoc tests was
used with treatment, a between-subjects variable and prepulse
intensity, a within-subjects variable. PPI values were also shown as
average PPI (%) of the three prepulse intensities and analyzed
using one-way ANOVA with Dunnett’s test or t-test. In PPI
analysis of APO-SUS/UNSUS rats (Figure 3), repeated-measures
two-way ANOVA with bonferroni post hoc tests was used with
treatment, a between-subjects variable and prepulse intensity, a
within-subjects variable. PPI values were also shown as average
PPI (%) of the three prepulse intensities and compared between
genotypes. Here, two-way ANOVA with bonferroni post hoc tests
was used and genotype and treatment were between-subjects
variables. In stereotypy analysis of mice (Figure 5), two-way
ANOVA with bonferroni post hoc tests was used with apomor-
phine dose and MCH dose, between-subjects variables. F values
shown in the result section indicate main effect of treatment or
genotype as described on the text unless indicated as genotype6
treatment interaction analysis. For brevity, the main effects of
prepulse intensity are not being discussed since they were always
significant.
Results
Startle and PPI responses in mice subjected to MCH
MCH was tested for its effects on startle responses and PPI.
Mice were injected with vehicle or MCH (1 nmole) and then
subjected to sessions comprised of pulse-alone trials (p120) and
prepulse+pulse trials (pp3p120, pp6p120, pp12p120). MCH had
no effect on startle (Figure 1A). The inhibition of the startle
response by the prepulse was measured and expressed as percent
of PPI. PPI increased with increasing prepulse intensities
(Figure 1B) and MCH had no effect on PPI levels (Figure 1B,C)
when compared to the vehicle-injected group.
The MCH System and Psychiatric Disorders
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apomorphine-induced PPI deficit in mice
Because we have shown that activation of the MCH system
potentiates DA-induced cell firing and cocaine-induced hyperac-
tivity [37], we investigated whether MCH affects apomorphine-
induced PPI deficits. The mixed D1/D2 agonist, apomorphine
disrupted PPI dose-dependently (Figure 2A) [50]. At first, an
intermediate dose of apomorphine, 0.75 mg/kg, was chosen to test
the effect of variable amounts of MCH. Vehicle or MCH (0.7 and
1 nmole) was injected prior to apomorphine injections. We found
that MCH dose-dependently increases apomorphine-induced PPI
deficits (F[2,32]=13.54, p,0.0001; Figure 2B) as also shown as an
average of the PPI values upon 3 prepulse intensities
(F[2,32]=13.54, p,0.0001; Figure 2D). The effect of MCH was
inhibited by co-administration of a specific MCH1R antagonist,
TPI 1361-17 (3 nmole) (p=0.0378; Figure 2D), confirming that
the MCH effects are MCH1R specific. Pretreatment by TPI 1361-
17 alone did not affect the apomorphine-induced PPI disruption
(Figure 2D). Apomorphine at higher doses (2.5 mg/kg) exerted an
enhanced PPI deficit when compared to the 0.75 mg/kg dose
which reached saturating effects (Figure 2A). At this dose, MCH
could not further increase the PPI deficit (Figure 2C). This is
further evidenced when the effects of MCH (1 nmole) were
compounded as a function of apomorphine concentration. MCH
decreased PPI level at lower apomorphine concentrations
(F[2,23]=6.65, p=0.0053; Figure S1) but this response reaches a
ceiling effect at high doses (Figure 2C).
Startle reactivity levels after drug injections were also examined.
Apomorphine significantly decreased startle reactivity at 2.5 mg/
kg, but not at 0.75 mg/kg (Table S1). Additional injections of
MCH and/or the MCH1R antagonist, TPI 1361-17 prior to
apomorphine did not affect startle reactivity.
Role of the MCH system in modulating PPI in APO-SUS
and APO-UNSUS rats
Since MCH increased apomorphine-induced PPI deficits in
mice, we examined its role in two outbred rat lines that have
different susceptibility to apomorphine, the APO-SUS and APO-
UNSUS strains of Wistar rats. We first analyzed mRNA
expression levels of the MCH precursor (pMCH) by in situ
hybridization in the lateral hypothalamus (LH), the central site of
MCH synthesis (Figure 3A,B). We found that the level of pMCH
mRNA expression was significantly higher in the LH region (near
22.75 mm from bregma) of APO-SUS rats than that of APO-
UNSUS rats (Figure 3A,B). Then, APO-SUS and APO-UNSUS
rats were compared to inbred wild type Wistar rats for their
responses to PPI (Figure 3C,D). Wistar rats displayed an
intermediate PPI phenotype when compared to APO-UNSUS
or APO-SUS rats but this was non-significant. APO-SUS rats
however exhibited a significant disrupted PPI when compared to
APO-UNSUS rats (*p,0.05 vs. APO-UNSUS; Figure 3C,D) (see
also [14]). We therefore proceeded by comparing APO-SUS and
APO-UNSUS rats to each others.
In view of the higher pMCH levels found in APO-SUS versus
APO-UNSUS rats, we tested whether administration of the
MCH1R antagonist TPI 1361-17 affects PPI in these rats
(Figure 3H–J). TPI 1361-17 (10 nmole) did not change PPI in
APO-UNSUS rats (Figure 3H) but significantly increased PPI in
APO-SUS rats (F[1,24]=4.72, p=0.04; prepulse intensity6treat-
ment, F[2,48]=5.28, p=0.008; Figure 3I). Noteworthy, TPI 1361-
17 did not affect startle responses in APO-UNSUS and APO-SUS
rats (Figure S2B). Conversely, we tested whether MCH injection
can decrease PPI in APO-UNSUS rats. Central injections of
MCH differentially affected PPI in these two lines of rats
(genotype6MCH treatment F[1,42]=5.73, p=0.02; genotype6
prepulse intensity6MCH treatment F[2,84]=3.41, p=0.04;
Figure 3G). MCH (10 nmole) significantly reduced PPI in APO-
UNSUS rats (F[1,21]=10.56, p=0.004; prepulse intensity6treat-
ment, F[2,42]=6.30, p=0.004; Figure 3E), but not in APO-SUS
rats (Figure 3F). APO-SUS rats were also found to exhibit higher
startle reactivity relative to APO-UNSUS rats (F[1,42]=9.36,
p=0.004; Figure S2A) (See also [14]). Importantly, MCH
injection did not affect startle reactivity in APO-UNSUS and
APO-SUS rats (Figure S2A).
Role of the MCH system in modulating dizocilpine-
induced PPI deficit in mice
Dizocilpine (MK-801) is a non-competitive NMDA receptor
antagonist that has been shown to also disrupt PPI [50] yet
through a mechanism distinct from that of the DA agonist,
apomorphine [44]. We analyzed whether acute MCH injection
could modulate dizocilpine-induced PPI deficit using the same
paradigm that was used for apomorphine. Dizocilpine dose-
dependently disrupted PPI (Figure 4A). The intermediate dose of
dizocilpine, 0.3 mg/kg, was chosen to test the effect of MCH.
Mice were injected either with vehicle or MCH (1 nmole) prior to
Figure 1. MCH effects on PPI in mice. A. Startle reactivities after vehicle or MCH (1 nmole) injection in mice (n=8–9). Values represent mean
startle reactivity 6 SEM. B. PPI levels in mice after MCH (1 nmole) injection (n=8–9). Values represent mean % PPI 6 SEM. C. Average of PPI values
after MCH injections in mice. Values represent average of % PPI elicited by three prepulse intensities 6 SEM.
doi:10.1371/journal.pone.0019286.g001
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(F[2,29]=7.64, p=0.002; Figure 4B) but MCH did not significantly
affect the dizocilpine-induced PPI deficit as further shown when
the percent of PPI is compounded as an average of the PPI values
upon 3 prepulse intensities (Figure 4C).
Role of the MCH system in modulating apomorphine-
induced stereotyped behaviors in mice and rats
Apomorphine induces stereotyped behaviors in laboratory
animals. To study whether acute activation of the MCH system
affects apomorphine-induced stereotypies, vehicle or MCH
Figure 2. MCH effects on apomorphine-induced PPI deficits in mice. A. Effect of apomorphine (0, 0.75, 2.5, 5 mg/kg) on PPI (**p,0.01 vs.
VEH, one-way ANOVA, with Dunnett’s test; n=5–21). Values represent average of % PPI elicited by three prepulse intensities 6 SEM. B. PPI after MCH
pretreatment (0, 0.7, 1 nmole) in apomorphine (0.75 mg/kg)-treated mice (*p,0.05, **p,0.01, ***p,0.001 vs. VEH+APO 0.75, two-way ANOVA with
Bonferroni test; n=8–19). C. PPI after MCH pretreatment (0, 1 nmole) in apomorphine (2.5 mg/kg)-treated mice (n=8). Values (B–C) represent mean
% PPI 6 SEM. D. Average of PPI values after MCH and/or TPI 1361-17 pretreatment in apomorphine-treated mice (
+++p,0.001, dose effect, one-way
ANOVA; **p,0.01 vs. APO 0.75, one-way ANOVA with Dunnett’s test;
#p,0.05 vs. APO 0.75+MCH1, t-test;
nsp.0.05 vs. APO 0.75+MCH1+TPI 3, t-test;
n=8–19). Values represent average of % PPI elicited by three prepulse intensities 6 SEM.
doi:10.1371/journal.pone.0019286.g002
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PLoS ONE | www.plosone.org 5 July 2011 | Volume 6 | Issue 7 | e19286Figure 3. MCH effects on PPI in APO-UNSUS and APO-SUS rats. A. Autoradiographic images illustrating the pMCH expression patterns in
hypothalamic areas of APO-UNSUS and APO-SUS rats approximately at 22.5, 22.75 and 23 mm from bregma. B. pMCH mRNA levels in the lateral
hypothalamus (LH) at 22.75 from bregma of APO-UNSUS and APO-SUS rats (*p,0.05 vs. APO-UNSUS, t-test; n=5). C. PPI levels of naı ¨ve APO-UNSUS,
wild type Wistar and APO-SUS rats (*p,0.05 vs. APO-UNSUS, two-way ANOVA with bonferroni test; n=15). Values represent mean % PPI 6 SEM. D.
Average PPI level of naı ¨ve APO-UNSUS, wild type Wistar and APO-SUS rats (*p,0.05 vs. APO-UNSUS, one-way ANOVA with bonferroni test; n=15).
Values represent average of % PPI upon three prepulse intensities 6 SEM. E. Effect of MCH (10 nmole) on PPI in APO-UNSUS rats (***p,0.001 vs. VEH,
two-way ANOVA with Bonferroni test; n=10–13). F. Effect of MCH (10 nmole) on PPI in APO-SUS rats (n=10–13). G. Average of PPI values after VEH or
MCH (10 nmole) injections in APO-UNSUS and APO-SUS rats (**p,0.01,
#p,0.05 vs. VEH-treated APO-UNSUS rats, two-way ANOVA with Bonferroni
test; n=10–13). H. Effect of TPI 1361-17 (10 nmole) on PPI in APO-UNSUS rats (n=12–13). I. Effect of TPI 1361-17 (10 nmole) on PPI in APO-SUS rats
(**p,0.01 vs. VEH, two-way ANOVA with Bonferroni test; n=13). J. Average of PPI values after VEH or TPI 1361-17 (10 nmole) injections in APO-
UNSUS and APO-SUS rats (
##p,0.01 vs. VEH-treated APO-UNSUS, *p,0.05 vs. VEH-treated APO-SUS, two-way ANOVA with Bonferroni test; n=12–
13). Data (E,F,H,I) are expressed as mean % PPI 6 SEM. Data (G,J) represent average of % PPI elicited by three prepulse intensities 6 SEM.
doi:10.1371/journal.pone.0019286.g003
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into mice. The animals were observed and recorded every min for
a total of 30 min. Stereotyped behaviors were scored using a rating
scale [48]. MCH alone did not induce any stereotyped behaviors
(Figure 5A). As expected, apomorphine dose-dependently induced
stereotyped behaviors (F[2,39]=83.12, p,0.0001; Figure 5A).
However, MCH had no effect on this induction (Figure 5A).
To study whether the MCH system modulates apomorphine-
induced stereotyped behavior in rats that are selectively bred for a
differential stereotyped response to apomorphine, the effect of
MCH was also tested in APO-SUS and APO-UNSUS rats. As
expected, apomorphine strongly increased stereotyped gnawing in
APO-SUS rats but not in APO-UNSUS rats (genotype6apomor-
phine treatment F[1,36]=56.72, p,0.0001; Figure S3A,B) (See also
[17]). The gnawing scores of APO-SUS and APO-UNSUS rats
were significantly different from those of wild type Wistar rats
(Figure 5B). Intriguingly, neither MCH nor TPI 1361-17 changed
stereotyped behavior in both types of rats (Figure 5C,D).
Discussion
The MCH system has been shown to regulate DA-related
responses [37,38,40]. The MCH receptor is highly expressed in
the limbic part of the brain where DA receptors are predominantly
expressed such as the nucleus accumbens shell (NAcSh) and the
prefrontal cortex (PFC) [34,36,47]. The MCH receptor is
expressed at low levels in the caudate putamen [36], which
suggests that it may be able to modulate the dopamine tone
selectively in the mesocorticolimbic system. The MCH receptor is
co-localized with the dopamine D1 and D2 receptors in the
NAcSh [37,38]. MCH receptor antagonists not only reduce food
intake, but are also anxiolytic, antidepressant and inhibit cocaine
reward [37,51–53]. Furthermore, a human linkage analysis has
indicated a possible association between the MCH1 receptor locus
and schizophrenia and bipolar disorders [35]. Therefore, we
hypothesized that the MCH system might be involved in another
dopamine-related response, sensorimotor gating and investigated
this hypothesis by using the PPI behavioral paradigm in two
rodent systems, apomorphine-treated mice and apomorphine-
susceptible rats that were previously found to have disrupted PPI
[14].
We show that central injections of MCH in mice do not affect
startle or PPI responses. However, because we have previously
shown that MCH alone does not induce cellular firing in the
NAcSh neurons, but potentiates dopamine D1 plus D2 agonist-
induced cellular firing [37], we hypothesized that MCH may affect
PPI in mice when it is combined with a dopamine agonist. We
therefore used the D1/D2 agonist apomorphine, which is known
to induce PPI deficits. First, we found that MCH enhances
apomorphine-induced PPI deficits dose dependently. This en-
hancement is seen at low doses of apomorphine (0.75 mg/kg) and
is not detected at saturating doses (2.5 mg/kg) which indicates that
MCH can potentiate the effects of low concentrations of
apomorphine but cannot increase the effects of saturating doses
Figure 4. MCH effects on dizocilpine-induced PPI deficits in mice. A. Effect of dizocilpine (0, 0.1, 0.3, 1 mg/kg) on PPI (**p,0.01 vs. VEH, one-
way ANOVA, Dunnett’s test; n=5–13). Values represent average of % PPI upon three prepulse intensities 6 SEM. B. PPI levels after MCH pretreatment
(0, 1 nmole) in dizocilpine (0, 0.3 mg/kg)-treated mice (*p,0.05, **p,0.01, ***p,0.001 vs. VEH, two-way ANOVA with Bonferroni test; n=8–12).
Values represent mean % PPI 6 SEM. C. Average of PPI value after MCH pretreatment on dizocilpine injections (**p,0.01 vs. VEH,
nsp.0.05 vs
VEH+DIZ0.3, one-way ANOVA with Bonferroni test; n=8–12). Values represent average of % PPI from three prepulses 6 SEM.
doi:10.1371/journal.pone.0019286.g004
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specific MCH1R antagonist, TPI 1361-17. Thus, MCH is able to
potentiate apomorphine-induced PPI deficits, in a manner similar
to its effects on DA-induced NAcSh firing and on cocaine-induced
hyperactivity [37]. It is important to note that MCH was found to
enhance apomorphine-induced PPI deficits without affecting
startle reactivity.
We then extended these studies by using the APO-SUS and
APO-UNSUS rat model. These animals have been selected and
bred to exhibit differences in their susceptibility to apomorphine
[42]. APO-SUS rats display a more responsive accumbal
catecholaminergic system [15,16] and a decreased PPI [14] when
compared to APO-UNSUS rats. This difference is consistent with
the higher levels of dopamine found in the NAc of novelty exposed
APO-SUS rats when compared to that of APO-UNSUS rats [15].
These outbred rats represent a model in which differences in the
dopamine tone exist naturally and they are therefore useful to
evaluate the effects of modulators of the dopamine system (for
review [42]). First, we found significantly higher pMCH mRNA
levels in the LH of APO-SUS versus APO-UNSUS rats, a first
indication that the MCH system may be involved in the
phenotypic differences exhibited by these rat strains. The fact
that LH neurons project to the mesocorticolimbic pathway [36,47]
is a further indication that the MCH system may modulate PPI
differently in the two strains. Indeed, when MCH was adminis-
tered to both rat strains, it disrupted PPI only in APO-UNSUS
rats that exhibit lower pMCH levels. This effect is in line with the
MCH potentiating effects we found in mice. On the other hand,
the fact that MCH injection did not disrupt PPI in the APO-SUS
rats is in line with their high basal pMCH levels and the
hyperdopaminergic activity of their mesolimbic DA pathway
[15,16] which may not be increased further by exogenous MCH
injection. The apparent discrepancy between the MCH effects in
apomorphine-untreated mice and APO-UNSUS rats may be
related to species differences such as these found in dopamine
levels (as inferred by tyrosine hydroxylase levels [54,55]) and
MCH levels [56] and will need to be analyzed further. Most
importantly, when the MCH system was blocked by the antagonist
TPI 1361-17, significant increases in PPI were found in APO-SUS
but not in APO-UNSUS rats. This correlates well with the higher
pMCH mRNA levels found in the LH of APO-SUS rats and with
our hypothesis that only activated dopamine systems can be
modulated by MCH.
Noncompetitive NMDA receptor antagonists such as PCP and
dizocilpine (MK-801) disrupt PPI [2] independently of the DA
system because neither D1 nor D2 antagonists reverse PCP or
dizocilpine-induced PPI deficits [12,13], and since dizocilpine
disrupts PPI in both D1R KO mice and D2R KO mice [44]. We
investigated whether the MCH system modulates the PPI
disrupted by dizocilpine. MCH injections did not change the
Figure 5. Apomorphine-induced stereotyped behaviors upon MCH injection. A. Effect of MCH (0, 1 nmole) on apomorphine (0, 0.5,
0.75 mg/kg)-induced stereotyped behaviors in mice (***p,0.001 vs. VEH, two-way ANOVA with Bonferroni test; n=5–10). B. Stereotypy counts in
APO-UNSUS, wild type Wistar and APO-SUS rats after apomorphine (1.5 mg/kg) injections (*p,0.05 ***p,0.001 vs Wistar
###p,0.001 vs APO-
UNSUS, one-way ANOVA with bonferroni’s posttests; n=10–15). C. Effect of MCH (10 nmole) and TPI 1361-17 (10 nmole) on apomorphine (1.5 mg/
kg)-induced stereotyped behavior in APO-UNSUS rats (n=10–13). D. Effect of MCH (10 nmole) and TPI 1361-17 (10 nmole) on apomorphine (1.5 mg/
kg)-induced stereotyped behavior in APO-SUS rats (n=11–13). Values (A–D) represent total stereotypy counts 6 SEM.
doi:10.1371/journal.pone.0019286.g005
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the MCH system regulates the PPI modulated by the activity of
the DA system, but not by the activity of the NMDA receptor-
involved glutamate system.
Stereotyped behaviors are also regulated by the DA system.
Indeed, the efficacy of D2R–related antipsychotics has been
commonly tested against apomorphine-induced stereotypies. These
responses are however thought to rely on DA receptors in the
caudate putamen, a region important in the regulation of motor
activity [26,27]. In mice, MCH alone did not induce any
stereotypies and had no significant effect on apomorphine-induced
stereotypies. This result is consistent with the low level of MCH1R
expression found in the caudate putamen [36], a level that is
apparently not sufficient to potentiate an apomorphine-induced
response as it does in the mouse nucleus accumbens, the region that
regulates PPI [8,9]. This finding is also consistent with the finding
that MCH1R KO mice exhibit behavioral differences that are
mostly associated with the mesolimbic dopamine system [40,41,57].
In line with our findings in mice, the MCH system did not modulate
stereotyped behaviors in both APO-UNSUS and APO-SUS rats.
In summary, we show that in mice the MCH system acutely
increases apomorphine-induced PPI disruption, but does not affect
dizocilpine-induced PPI deficits. In rats, a strain which exhibit
higher PPI deficits (APO-SUS) displays significantly higher pMCH
mRNA levels. MCH administration decreases PPI in the strain
with lower PPI deficit (APO-UNSUS) but not in APO-SUS rats.
Moreover blockade of the MCH system increases PPI in APO-
SUS rats, but not in APO-UNSUS rats. On the other hand, the
MCH system does not affect apomorphine-induced stereotypies in
mice and rats. Taken together these data lead us to conclude that
the MCH system potentiates dopamine-related responses selec-
tively and spatially, but does not modulate the related glutamate-
directed PPI response nor the nigrostriatal system-associated
stereotypies. Thus, the MCH system may be targeted for the
development of drugs for neuropsychiatric disorders that are
related to the overactivity of the mesolimbic DA system.
Supporting Information
Figure S1 Percent change of MCH-induced PPI upon
increasing doses of apomorphine. Percent changes of PPI
level as function of apomorphine concentrations (0, 0.4 and
0.75 mg/kg) in the presence of MCH (1 nmole). Values represent
percent changes of PPI at each dose of apomorphine (
##p,0.01,
dose effect, one-way ANOVA; **p,0.01 vs. APO 0+MCH1, one-
way ANOVA with Dunnett’s test; n=8–9).
(TIF)
Figure S2 Startle reactivities of APO-UNSUS and APO-
SUS rats upon MCH or MCH1R antagonist (TPI 1361-17)
injections. A. Startle reactivity of APO-UNSUS and APO-SUS
rats upon vehicle or MCH injections (two-way ANOVA, genotype
effect F[1,42]=9.362 p=0.0039, treatment effect F[1,42]=1.625
p=0.2095; bonferroni test *p,0.05 vs. VEH treated APO-
UNSUS; n=10–13). B. Startle reactivity of APO-UNSUS and
APO-SUS rats upon vehicle or TPI 1361-17 injections (two-way
ANOVA, genotype effect F[1,47]=10.77 p=0.0019, treatment
effect F[1,47]=3.962 p=0.0524; n=12–13). Values represent
mean startle reactivity 6 SEM.
(TIF)
Figure S3 Stereotyped behaviors in APO-UNSUS and
APO-SUS rats. Individual differences in apomorphine-induced
stereotyped gnawing behaviors in APO-UNSUS and APO-SUS
rats (two-way ANOVA, genotype6apomorphine effect:
F[1.36]=56.72, p,0.0001; rat type separated into Figure S3A
and S3B due to large differences in their Y-axis). A. Stereotypy
counts in APO-UNSUS rats upon veh or apomorphine (1.5 mg/
kg) injections (Bonferroni posttests, apomorphine effect p.0.05).
B. Stereotypy counts in APO-SUS rats upon veh or apomorphine
(1.5 mg/kg) injections (Bonferroni posttests, apomorphine effect
***p,0.001). Values (A–B) represent total stereotypy counts 6
SEM.
(TIF)
Figure S4 Stereotaxic coordinates of lateral hypothala-
mus for pMCH mRNA quantification. Red circles indicate
lateral hypothalamic region which was used to quantify pMCH
mRNA levels.
(TIF)
Table S1 Startle reactivities upon apomorphine and/or
MCH/MCH1R antagonist (TPI 1361-17) injections.
(TIF)
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